Please login to the form below

Not currently logged in
Email:
Password:

Pfizer agrees MoU with Chinese firm

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co that includes selling and distributing an unnamed Pfizer product in China. 

The companies plan to explore future co-operation opportunities, including further distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities. 

The companies also expect to strengthen their existing co-operation for the promotion of Pfizer's Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for active immunisation of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia. 

David Simmons, president and general manager, emerging markets and established products of Pfizer, said: "Our intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of our commitment to expand our presence in China in collaboration with the local industry." 

Shanghai Pharmaceutical has been one of Pfizer's major partners in China for years and is its largest distribution customer in the market.

21st April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics